** Shares of cancer drug developer Tempest Therapeutics TPST.O rise ~9% to $7.79 in extended trading
** TPST says it is exploring strategic alternatives, such as mergers or partnerships, to advance its cancer treatment programs
** Company's pipeline includes its lead liver cancer drug, amezalpat, and TPST-1495, a treatment for familial adenomatous polyposis, a rare genetic disorder
** Amezalpat received both Orphan Drug and Fast Track designations from the US FDA
** As of last close, stock down 34% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.